Orion Oyj — Earnings Release 2019

Aug 7, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

ORION CORPORATION PRESS RELEASE 7 AUGUST 2019 at 10.30 am EEST             

Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone

Sales of Nubeqa® (darolutamide), jointly developed by Orion Corporation and Bayer for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), has started in the USA. In connection with the successful commercialization of darolutamide in the USA, Orion receives from Bayer a EUR 45 million milestone. Orion will book the milestone in its third quarter 2019 result. The booking has no impact on Orion’s outlook for 2019 as the EUR 45 million milestone has been included in the financial guidance provided by the company.

Darolutamide is currently not approved by the European Medicines Agency or any other health authority outside the USA.

Contact person:

Tuukka Hirvonen, Investor Relations and Financial Communications, Orion Corporation

tel. +358 010 426 2721

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.